Gabapentinoid use in French most precarious populations: Insight from Lyon Permanent Access to Healthcare (PASS) units, 2016-1Q2021.
gabapentin
misuse
pregabalin
prescription drug abuse
Journal
Fundamental & clinical pharmacology
ISSN: 1472-8206
Titre abrégé: Fundam Clin Pharmacol
Pays: England
ID NLM: 8710411
Informations de publication
Date de publication:
Apr 2022
Apr 2022
Historique:
revised:
11
08
2021
received:
07
06
2021
accepted:
07
09
2021
pubmed:
10
9
2021
medline:
16
3
2022
entrez:
9
9
2021
Statut:
ppublish
Résumé
Gabapentinoids (i.e., gabapentin and pregabalin) are medications approved for epilepsy, chronic pain, or generalized anxiety disorder. Recently, there have been regular reports of misuse of pregabalin, and to a lesser extent, gabapentin, in particular among opioid and polydrug users. To longitudinally explore the amounts of gabapentinoids dispensed in Lyon's Permanent Access to Healthcare (PASS) units, which offer permanent and free healthcare to precarious populations with no healthcare insurance coverage. We collected the amounts of pregabalin and gabapentin dispensed in the three PASS units of Lyon and calculated the average doses dispensed monthly between 2016 and the first quarter of 2021 (1Q2021), with and without adjustment for the number of dispensing visits. The total doses of gabapentinoid dispensed every month in Lyon's PASS units displayed a 1233% increase for pregabalin, and a 1185% increase for gabapentin, between 2016 and 1Q2021. When adjusted for the number of visits, this increase reached a factor of 8.5 for pregabalin and 8.3 for gabapentin, respectively. However, while the increase in pregabalin dispensing was constant throughout the study period, gabapentin total dispensed doses were more fluctuating over time, and the rise of dispensations was thus less straightforward. Our study reveals a local but substantial increase in gabapentinoid use in populations with no social insurance. These findings should be confirmed more widely and plead for the systematic collection of anonymous patient data in free healthcare centers in France.
Sections du résumé
BACKGROUND
BACKGROUND
Gabapentinoids (i.e., gabapentin and pregabalin) are medications approved for epilepsy, chronic pain, or generalized anxiety disorder. Recently, there have been regular reports of misuse of pregabalin, and to a lesser extent, gabapentin, in particular among opioid and polydrug users.
OBJECTIVES
OBJECTIVE
To longitudinally explore the amounts of gabapentinoids dispensed in Lyon's Permanent Access to Healthcare (PASS) units, which offer permanent and free healthcare to precarious populations with no healthcare insurance coverage.
METHODS
METHODS
We collected the amounts of pregabalin and gabapentin dispensed in the three PASS units of Lyon and calculated the average doses dispensed monthly between 2016 and the first quarter of 2021 (1Q2021), with and without adjustment for the number of dispensing visits.
RESULTS
RESULTS
The total doses of gabapentinoid dispensed every month in Lyon's PASS units displayed a 1233% increase for pregabalin, and a 1185% increase for gabapentin, between 2016 and 1Q2021. When adjusted for the number of visits, this increase reached a factor of 8.5 for pregabalin and 8.3 for gabapentin, respectively. However, while the increase in pregabalin dispensing was constant throughout the study period, gabapentin total dispensed doses were more fluctuating over time, and the rise of dispensations was thus less straightforward.
CONCLUSION
CONCLUSIONS
Our study reveals a local but substantial increase in gabapentinoid use in populations with no social insurance. These findings should be confirmed more widely and plead for the systematic collection of anonymous patient data in free healthcare centers in France.
Substances chimiques
Analgesics
0
Analgesics, Opioid
0
Pregabalin
55JG375S6M
Gabapentin
6CW7F3G59X
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
448-452Informations de copyright
© 2021 Société Française de Pharmacologie et de Thérapeutique.
Références
Calandre EP, Rico-Villademoros F, Slim M. Alpha2delta ligands, gabapentin, pregabalin and mirogabalin: a review of their clinical pharmacology and therapeutic use. Expert Rev Neurother. 2016;16(11):1263-1277.
Frye M, Moore K. Gabapentin and pregabalin. In Schatzberg, Alan F.; Nemeroff, Charles B. (eds.). The American Psychiatric Publishing Textbook of Psychopharmacology. American Psychiatric Pub, (2009) pp. 767-777. https://doi.org/10.1176/appi.books.9781585623860.as38
Evoy KE, Sadrameli S, Contreras J, Covvey JR, Peckham AM, Morrison MD. Abuse and misuse of pregabalin and gabapentin: a systematic review update. Drugs. 2021;81(1):125-156.
Driot D, Jouanjus E, Oustric S, Dupouy J, Lapeyre-Mestre M. Patterns of gabapentin and pregabalin use and misuse: results of a population-based cohort study in France. Br J Clin Pharmacol. 2019;85(6):1260-1269.
Tambon M, Ponté C, Jouanjus E, et al. Gabapentinoid abuse in France: evidence on health consequences and new points of vigilance. Front Psych. 2021;12:639780.
Official Journal of the French Republic. [Ordinance of 12 Feb 2021, implementing a part of the regulation of narcotics to pregabalin-based medications, and determining the duration of prescription]. (24 Feb, 2021). https://www.legifrance.gouv.fr/eli/arrete/2021/2/12/SSAP2103145A/jo/texte (accessed 17 May 2021).
Bockbrader HN, Wesche D, Miller R, Chapel S, Janiczek N, Burger P. A comparison of the pharmacokinetics and pharmacodynamics of pregabalin and gabapentin. Clin Pharmacokinet. 2010;49(10):661-669.
Schifano F, Chiappini S. Pregabalin: a range of misuse-related unanswered questions. CNS Neurosci Ther. 2019;25(5):659-660.
Agence Nationale du Médicament et des produits de santé (ANSM). Prégabaline (Lyrica et génériques): modification des conditions de prescription et délivrance pour limiter le mésusage. [Pregabalin (Lyrica and generics): modifications of prescribing and dispensing conditions in view of limiting misuse]. 05/21/2021 https://ansm.sante.fr/actualites/pregabaline-lyrica-et-generiques-modification-des-conditions-de-prescription-et-delivrance-pour-limiter-le-mesusage (accessed 23 July 2021).
Georges-Tarragano C. The permanence of access to health care: a tradition of hospitality and innovative organizational model. Rev Med Interne. 2015;36(1):38-41.
Tapié de Celeyran F, Girardeau Y, Khan S, Morinet F, Georges-Tarragano C. Health-care access for migrants in France. Lancet. 2013;382(9906):1704.
Agence Nationale du Médicament et des produits de santé (ANSM). Rapport Prégabaline [Pregabalin Report]. 02/24/2020. https://ansm.sante.fr/uploads/2021/03/01/20200224-rapport-pregabaline-2020.pdf (accessed 17 May 2021).
Hourdet A, Rénier M, Van de Steeg F, Rieutord G, de Champs Léger H. État de santé des patients se déclarant mineurs non accompagnés et non reconnus mineurs : enquête rétrospective au sein de la Permanence d'accès aux soins de santé de l'Hôtel-Dieu [Health condition of patients self-reporting as unaccompanied minors and not recognized as such: Retrospective survey within the Hôtel-Dieu health platform PASS]. Bull Epidémiol Hebd (2020). (27):531-537. https://www.santepubliquefrance.fr/regions/ile-de-france/documents/article/2020/etat-de-sante-des-patients-se-declarant-mineurs-non-accompagnes-et-non-reconnus-mineurs-enquete-retrospective-au-sein-de-la-permanence-d-acces-au (accessed 19 May 2021).
Hägg S, Jönsson AK, Ahlner J. Current evidence on abuse and misuse of gabapentinoids. Drug Saf. 2020;43(12):1235-1254.